Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(3)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05453721Not ApplicableCompleted

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）

Role: collaborator

NCT07170345Recruiting

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Role: collaborator

NCT04922853Phase 3Active Not Recruiting

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Role: collaborator

NCT05439135Not ApplicableRecruiting

Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract

Role: collaborator

NCT06574659Not ApplicableRecruiting

Noninvasive Ventilation Breathing Test Guiding Weaning in Patients With Acute Hypoxic Respiratory Failure

Role: collaborator

NCT06501651Phase 4Not Yet Recruiting

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Role: collaborator

All 6 trials loaded